Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Golimumab for Adherence in Rheumatoid Arthritis

Trial Profile

Golimumab for Adherence in Rheumatoid Arthritis

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 30 Dec 2018

At a glance

  • Drugs Golimumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms GO FAR
  • Sponsors Janssen Inc
  • Most Recent Events

    • 03 Dec 2018 Planned End Date changed from 1 Dec 2020 to 21 Dec 2020.
    • 03 Dec 2018 Planned initiation date changed from 1 Nov 2018 to 7 Jan 2019.
    • 08 Nov 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top